Literature DB >> 27146268

PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo.

Joseph Ochaba1, Alex Mas Monteys2, Jacqueline G O'Rourke3, Jack C Reidling4, Joan S Steffan5, Beverly L Davidson6, Leslie M Thompson7.   

Abstract

The disruption of protein quality control networks is central to pathology in Huntington's disease (HD) and other neurodegenerative disorders. The aberrant accumulation of insoluble high-molecular-weight protein complexes containing the Huntingtin (HTT) protein and SUMOylated protein corresponds to disease manifestation. We previously identified an HTT-selective E3 SUMO ligase, PIAS1, that regulates HTT accumulation and SUMO modification in cells. Here we investigated whether PIAS1 modulation in neurons alters HD-associated phenotypes in vivo. Instrastriatal injection of a PIAS1-directed miRNA significantly improved behavioral phenotypes in rapidly progressing mutant HTT (mHTT) fragment R6/2 mice. PIAS1 reduction prevented the accumulation of mHTT and SUMO- and ubiquitin-modified proteins, increased synaptophysin levels, and normalized key inflammatory markers. In contrast, PIAS1 overexpression exacerbated mHTT-associated phenotypes and aberrant protein accumulation. These results confirm the association between aberrant accumulation of expanded polyglutamine-dependent insoluble protein species and pathogenesis, and they link phenotypic benefit to reduction of these species through PIAS1 modulation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27146268      PMCID: PMC4942306          DOI: 10.1016/j.neuron.2016.03.016

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  70 in total

1.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

2.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

Review 3.  Repeat expansion disease: progress and puzzles in disease pathogenesis.

Authors:  Albert R La Spada; J Paul Taylor
Journal:  Nat Rev Genet       Date:  2010-04       Impact factor: 53.242

Review 4.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

5.  Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.

Authors:  Edward C Stack; James K Kubilus; Karen Smith; Kerry Cormier; Steven J Del Signore; Emmanuel Guelin; Hoon Ryu; Steven M Hersch; Robert J Ferrante
Journal:  J Comp Neurol       Date:  2005-10-03       Impact factor: 3.215

6.  Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors.

Authors:  Andrea Crotti; Christopher Benner; Bilal E Kerman; David Gosselin; Clotilde Lagier-Tourenne; Chiara Zuccato; Elena Cattaneo; Fred H Gage; Don W Cleveland; Christopher K Glass
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

7.  Multiple domains in Siz SUMO ligases contribute to substrate selectivity.

Authors:  Alison Reindle; Irina Belichenko; Gwendolyn R Bylebyl; Xiaole L Chen; Nishant Gandhi; Erica S Johnson
Journal:  J Cell Sci       Date:  2006-10-31       Impact factor: 5.285

8.  PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity.

Authors:  Bin Liu; Sheldon Mink; Kelly A Wong; Natalie Stein; Crescent Getman; Paul W Dempsey; Hong Wu; Ke Shuai
Journal:  Nat Immunol       Date:  2004-08-15       Impact factor: 25.606

9.  The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.

Authors:  Robert B Laprairie; Jordan R Warford; Sarah Hutchings; George S Robertson; Melanie E M Kelly; Eileen M Denovan-Wright
Journal:  J Neuroimmunol       Date:  2013-12-12       Impact factor: 3.478

Review 10.  Sumoylation in neurodegenerative diseases.

Authors:  Petranka Krumova; Jochen H Weishaupt
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

View more
  33 in total

Review 1.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

2.  Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice.

Authors: 
Journal:  Nat Neurosci       Date:  2017-03-20       Impact factor: 24.884

3.  Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.

Authors:  Amanda J Kedaigle; Jack C Reidling; Ryan G Lim; Miriam Adam; Jie Wu; Brook Wassie; Jennifer T Stocksdale; Malcolm S Casale; Ernest Fraenkel; Leslie M Thompson
Journal:  Hum Mol Genet       Date:  2020-01-15       Impact factor: 6.150

4.  Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease.

Authors:  Joshua D Crapser; Joseph Ochaba; Neelakshi Soni; Jack C Reidling; Leslie M Thompson; Kim N Green
Journal:  Brain       Date:  2020-01-01       Impact factor: 13.501

Review 5.  New developments in RAN translation: insights from multiple diseases.

Authors:  John Douglas Cleary; Laura Pw Ranum
Journal:  Curr Opin Genet Dev       Date:  2017-03-30       Impact factor: 5.578

6.  Mutant Huntingtin Disrupts the Nuclear Pore Complex.

Authors:  Jonathan C Grima; J Gavin Daigle; Nicolas Arbez; Kathleen C Cunningham; Ke Zhang; Joseph Ochaba; Charlene Geater; Eva Morozko; Jennifer Stocksdale; Jenna C Glatzer; Jacqueline T Pham; Ishrat Ahmed; Qi Peng; Harsh Wadhwa; Olga Pletnikova; Juan C Troncoso; Wenzhen Duan; Solomon H Snyder; Laura P W Ranum; Leslie M Thompson; Thomas E Lloyd; Christopher A Ross; Jeffrey D Rothstein
Journal:  Neuron       Date:  2017-04-05       Impact factor: 17.173

7.  Fractionation for Resolution of Soluble and Insoluble Huntingtin Species.

Authors:  Joseph Ochaba; Eva L Morozko; Jacqueline G O'Rourke; Leslie M Thompson
Journal:  J Vis Exp       Date:  2018-02-27       Impact factor: 1.355

8.  Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.

Authors:  Eva L Morozko; Joseph Ochaba; Sarah J Hernandez; Alice Lau; Isabella Sanchez; Iliana Orellana; Lexi Kopan; Joshua Crapser; Janet H Duong; Julia Overman; Silvia Yeung; Joan S Steffan; Jack Reidling; Leslie M Thompson
Journal:  J Huntingtons Dis       Date:  2018

9.  The ubiquitin conjugating enzyme Ube2W regulates solubility of the Huntington's disease protein, huntingtin.

Authors:  Bo Wang; Li Zeng; Sean A Merillat; Svetlana Fischer; Joseph Ochaba; Leslie M Thompson; Sami J Barmada; Kenneth M Scaglione; Henry L Paulson
Journal:  Neurobiol Dis       Date:  2017-10-03       Impact factor: 5.996

10.  SUMOylation and ubiquitination reciprocally regulate α-synuclein degradation and pathological aggregation.

Authors:  Ruth Rott; Raymonde Szargel; Vered Shani; Haya Hamza; Mor Savyon; Fatimah Abd Elghani; Rina Bandopadhyay; Simone Engelender
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.